#114 What Are the Generic and Biosimilar Industries Worried About? Current Competition Law Issues Impacting the Sector.

Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are the competition law issues faced by suppliers of those products? Adrian van den Hoven, Director General of trade association Medicines for Europe, joins John Roberti and Matthew Hall to discuss the key concerns of generic and biosimilar suppliers and also the dramatic impact of COVID-19 on them. Listen to this episode to learn more about the application of competition law to pharmaceuticals and the background to the 2020 comfort letter granted by the European Commission at the request of Medicines for Europe.

Adrian van den Hoven, Director General, Medicines for Europe

Hosted by:

John Roberti, Partner, Allen & Overy and Matthew Hall, Partner, McGuireWoods London LLP

#114 What Are the Generic and Biosimilar Industries Worried About? Current Competition Law Issues Impacting the Sector.

Adrian van den Hoven, Director General, Medicines for Europe

#113 Are “UDAPs” Protecting Consumers or Promoting Chaos? Exposing the Fault Lines under State Statutes Prohibiting Unfair and Deceptive Acts and Practices

#115 Are We Witnessing a Revolution? Putting the Debate Over Antitrust Reform Into Context.

Don't miss new episodes every Monday. Subscribe now!

CONTACT US

Find us on social!